alendronate / Generic mfg. - LARVOL DELTA

Yishen Qianggu Mixture formulation suppresses osteometabolic inflammation by modulating the IL-17/NF-κB/MAPK signaling axis. (PubMed, J Ethnopharmacol) - "YSQGM ameliorates bone metabolic imbalance in PMOP by suppressing proinflammatory mediators in the IL-17/NF-κB/MAPK signaling axis, providing novel mechanistic evidence for the use of TCM in PMOP prevention and treatment."

Journal • Inflammation • Osteoporosis • Rheumatology • FOS • IL17A • MAPK14 • PACERR • PTGS2

Comparative efficacy of therapeutic interventions for thalassemia-induced osteoporosis: A network meta-analysis (ASH 2025) - "Compared with control, significant improvement in BMD at Total Hip or Femoral Neck (Z-score) was observed in Zoledronic Acid [MD = 0.51; 95% CI: 0.27 to 0.75], Alendronate [MD = 0.37; 95% CI: 0.20 to 0.54], Pamidronate [MD = 0.27; 95% CI: 0.01 to 0.54], and Zinc [MD = 0.26; 95% CI: 0.09 to 0.43]. It emphasizes the critical role of bisphosphonates, nutritional supplementation, and novel agents in enhancing bone health and overall quality of life for this patient population. These findings provide essential guidance for clinicians in optimizing osteoporosis management for individuals with thalassemia."

Retrospective data • Beta-Thalassemia • Genetic Disorders • Osteoporosis • Rheumatology

Severe cutaneous adverse reactions to anti-osteoporosis drugs: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database and a review of published cases. (PubMed, Front Pharmacol) - "Denosumab (24%), alendronate (23.25%), and zoledronic acid (17.13%) were most frequently reported. Anti-osteoporosis drugs, notably bisphosphonates and strontium ranelate, are rarely linked to SCARs but may cause serious consequences. Increased clinical awareness, pre-treatment risk evaluation, and vigilant monitoring are essential for at-risk patients."

Adverse events • Journal • Real-world evidence • Dermatology • Osteoporosis • Rheumatology • Steven-Johnson Syndrome • Vasculitis

Combined Treatment with a C-Type Natriuretic Peptide Analog and Bisphosphonate Enhances Bone Growth in Growing Mice with Osteogenesis Imperfecta: A Pilot Study. (PubMed, J Bone Miner Res) - "This pilot study evaluated whether a CNP analog combined with alendronate (ALN) improves growth and bone mineral density in oim/oim (OIM) mice, a model of moderate-to-severe Type III OI...These results will inform optimal dosing for future studies. A full murine study is planned to further evaluate therapeutic potential for translation to humans."

Journal • Preclinical • Genetic Disorders • Musculoskeletal Diseases • Orthopedics

The efficacy and safety of romosozumab sequential therapy in postmenopausal women: A systematic review and meta-analysis. (PubMed, J Orthop) - "Sequential treatment with romosozumab followed by anti-resorptive agents (e.g., denosumab, alendronate) significantly reduced fracture incidence and increased BMD at the lumbar spine, total hip, and femoral neck compared to non-sequential therapy. Romosozumab sequential therapy may reduce fracture risk and improve BMD in postmenopausal women with osteoporosis, without a significant increase in short-term adverse events. However, evidence regarding new vertebral fractures and certain BMD outcomes remains limited in robustness, warranting further validation through high-quality, long-term studies."

Journal • Retrospective data • Review • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Fermented mealworm extract prevents concurrent bone and muscle loss by modulating RANKL-NFκB/MAPK signaling in ovariectomized mice. (PubMed, Bone) - "Female C57BL/6 N mice were divided into five groups: sham-operated, ovariectomized (OVX), OVX treated with two doses of FME (200 and 500 mg/kg, oral), and OVX treated with alendronate (Alen, 500 μg/kg, oral) as a positive control, for 15 weeks...Mechanistic analyses were performed mainly in the FME500 group, which downregulated NFκB/MAPK and upregulated IGF-1-PI3K-Akt in both bone and muscle. These results indicate that FME suppresses the postmenopausal concurrent bone and muscle loss by regulating RANKL-NFκB/MAPK and IGF-1-PI3K-Akt signaling pathways."

Journal • Preclinical • Muscular Atrophy • Osteoporosis • Rheumatology • Targeted Protein Degradation • FBXO32 • IGF1 • IL6 • MYOD1 • TNFA • TNFSF11

Cost-Effectiveness of Fracture Prevention in Postmenopausal Women With Early Breast Cancer in China. (PubMed, J Cachexia Sarcopenia Muscle) - "One-time BMD screening with selective alendronate for osteoporosis is cost-effective for Chinese women aged ≥ 60 receiving AIs, aligning with China's healthcare constraints. Universal therapy becomes favourable for older or high-risk subgroups. These data-driven findings support tailored strategies to optimise bone health management and resource allocation."

HEOR • Journal • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Musculoskeletal Diseases • Oncology • Rheumatology • Solid Tumor

Development of a Rifapentine-Loaded Alendronate-Conjugated PLGA-PEG Nanosystem: A Novel Bone-Targeted Strategy for Osteoarticular Tuberculosis Treatment with Enhanced Drug Delivery and Bone Regeneration. (PubMed, Int J Nanomedicine) - "The RPT/ALN-PLGA-PEG nanosystems demonstrated remarkable bone-targeting capability, sustained and potent antibacterial efficacy, and mitigation of bone destruction, coupled with the promotion of bone repair. These findings provide an innovative approach for addressing osteoarticular TB."

Journal • Fibrosis • Infectious Disease • Inflammation • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Proton Pump Inhibitors Are Associated With Increased Risk of Site-Specific Nonunion After Open Reduction Internal Fixation. (PubMed, J Orthop Trauma) - "Proton pump inhibitor (PPI) use was associated with increased nonunion risk, particularly in tibia/fibula and radius/ulna fractures. Younger patients demonstrated greater susceptibility to PPI-associated nonunion. The findings indicated that PPI exposure may have adversely affected fracture healing in specific anatomical or demographic subgroups and warranted further investigation."

Journal • Cardiovascular • Chronic Kidney Disease • Genetic Disorders • Hypertension • Musculoskeletal Diseases • Nephrology • Obesity • Orthopedics • Osteoporosis • Renal Disease • Rheumatology

Engineering of Metal-Organic Networks as Band-Aid for the Repair of Osteoporotic Bone Fractures. (PubMed, ACS Nano) - "In this work, we engineered a metal-organic network as a bone repair "band-aid" by integrating poly(ethylene glycol)-alendronate (PEG-ALN) conjugates with bioactive epigallocatechin gallate (EGCG), zinc, and calcium ions into a multifunctional scaffold...Mechanistically, the band-aid modulated macrophage polarization toward a pro-regenerative M2 phenotype and suppressed excessive osteoclast activity, thereby restoring the osteogenic-osteoclastic equilibrium. This study not only provides a therapeutic implant for osteoporotic bone repair but also proposes a strategy for designing immunomodulatory scaffolds that target the pathological bone microenvironment."

Journal • Inflammation • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Comparative Effects of Minodronate and Alendronate on Low Back Pain in Postmenopausal Osteoporosis and Age Influence: A Head-to-Head, Randomized Clinical Trial. (PubMed, Clin Interv Aging) - P=N/A | "Safety profiles were similar, supporting clinical selection based on dosing convenience and gastrointestinal tolerance. ClinicalTrials.gov number: NCT05673980 (08/12/2022)."

Clinical • Head-to-Head • Journal • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Osteoporosis • Pain • Rheumatology

Sequential dual-targeting biomimetic nanovesicles for bone marrow-specific delivery of bortezomib in multiple myeloma. (PubMed, Front Bioeng Biotechnol) - "Here, we report the design of a sequentially dual-targeted biomimetic nanoplatform that integrates the high affinity of alendronate for hydroxyapatite in the bone matrix with the homotypic targeting capability of MM cell membranes, thereby enabling a hierarchical "bone-first, tumor-next" delivery paradigm. Both in vitro and in vivo studies demonstrated that this nanoplatform significantly prolonged survival in MM-bearing mice: all animals in the PBS control group succumbed within 29 days, whereas 100% of BTZ@PLGA/EM-treated mice survived to day 45 (p < 0.001), accompanied by reduced systemic toxicity. Collectively, this work addresses a central challenge of drug delivery within the bone marrow niche and provides a promising strategy with strong translational potential for MM therapy."

Journal • Hematological Malignancies • Multiple Myeloma • Oncology

The role of amino bisphosphonates zoledronate and alendronate in shaping immunomodulatory profile and angiogenic potential of human periodontal ligament stem cells. (PubMed, PLoS One) - "In summary, these results suggest that therapeutic concentrations of ZOL and ALN influence the immunomodulatory ability of hPDLSCs by altering PD-L1 expression and reducing the angiogenic potential of hPDLSCs secretome. Both the modulation of inflammation and impairment of angiogenesis may induce unfavorable conditions in periodontal tissue, facilitating the development of osteonecrosis."

IO biomarker • Journal • Inflammation • CXCL8 • IL6 • PD-L1

The Impact of Fracture Liaison Services on Outcomes in Older Patients: A Systematic Review. (PubMed, Cureus) - "The most prescribed medications were zoledronic acid, denosumab, and alendronate. FLS can be an effective model to target the post-fracture care gap in older osteoporosis patients and improve outcomes, particularly medication initiation. Future studies should evaluate best practices for FLS programs."

Journal • Review • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Hydroxybutyl chitosan-based thermosensitive hydrogel enhanced osteoporotic bone regeneration through sustained release of alendronate and BMP-2. (PubMed, Carbohydr Polym) - "The hydrogel's enhanced efficacy in osteoporotic bone regeneration was validated using an osteoporotic rat calvarial defect model. This hydrogel demonstrated the convenience of injectability, dual-release functionality, and long-term controlled release characteristics, underscoring its translational potential for treating osteoporotic bone defects."

Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis

Bone antiresorptives as potential chelators for iron overload diseases. (PubMed, Biometals) - "Here, the iron binding and antioxidant effects of four bisphosphonates (etidronate, alendronate, tiludronate, and zoledronate) and strontium ranelate AR were studied in buffer and cell models, in order to verify their potential as alternative treatments of IOD in the absence of bone disease. Although measurable, the effect of physiological levels of calcium did not prevent the desired chelating and antioxidant effects of the bisphosphonates. Our results show that etidronate and tiludronate have valuable physicochemical properties that could be employed in a DR strategy for the treatment of IOD."

Journal • Hematological Disorders • Orthopedics

Theranostic Verteporfin-Conjugated Upconversion Nanoparticles for Cancer Treatment. (PubMed, Nanomaterials (Basel)) - "The synthesized core-shell upconversion nanoparticles (CS-UCNPs) were coated with new verteporfin (VP)-conjugated alendronate-terminated poly(N,N-dimethylacrylamide-co-2-aminoethyl acrylate) [Ale-P(DMA-AEA)] grafted with poly(ethylene glycol) (PEG). Under 980 nm NIR irradiation, CS-UCNP@Ale-P(DMA-AEA)-PEG-VP nanoparticles generated reactive oxygen species (ROS) due to the efficient energy transfer between CS-UCNPs and VP. In a pilot preclinical study, intratumoral administration of nanoparticle conjugates to mice, followed by exposure to NIR light, induced necrosis of pancreatic tumor and suppressed its growth."

Journal • Oncology • Pancreatic Cancer • Solid Tumor

Alendronate to Reduce Pelvic Insufficiency Fractures in Cervical Cancer Patients Undergoing Chemoradiation (clinicaltrials.gov) - P1/2 | N=65 | Not yet recruiting | Sponsor: Dr. Itay GoorAryeh

New P1/2 trial • Cervical Cancer • Musculoskeletal Diseases • Oncology • Solid Tumor

Alendronate-Based Polypeptide Hydrogels with Osteogenic Potential for Digital Light Processing. (PubMed, ACS Appl Mater Interfaces) - "A significant enhancement of hydrogel mechanical properties is observed, reaching Young's modulus values toward those observed for native bone. Furthermore, the presence of Ca2+ supports mineralization, fostering osteogenesis in seeded rat mesenchymal stem cells (rMSCs), indicating the potential to promote effective bone tissue regeneration."

Journal

Clinical Benefits of Denosumab vs Zoledronate in Postmenopausal Women Previously Treated with Alendronate: A Two-Year Retrospective Study. (PubMed, Drug Des Devel Ther) - "In postmenopausal osteoporosis patients transitioning from oral ALN to other antiresorptive therapies, Dmab is demonstrated superior efficacy over ZOL in lowering risk of new-onset vertebral and overall fractures and sustaining BMD improvements over 24 months. These findings suggest that Dmab may represent a preferential strategy for optimizing clinical outcomes in sequential anti-osteoporosis treatment protocols."

Clinical • Journal • Retrospective data • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Multisite Osteonecrosis to Long-term Corticoid Treatment: A Case Report. (PubMed, J Orthop Case Rep) - "CD, Bone marrow aspirate concentrate application, and alendronate have decreased the rate of progression of the disease in all joints except in the hips. Tensor fascia lata muscle pedicle grafting decreased progression in the hips."

Journal • Orthopedics • Pain

Bisphosphonate-related ocular adverse events: a pharmacovigilance study based on the FAERS database. (PubMed, Endocr Connect) - "Among 6,965 ocular AE reports for five BPs (alendronate, zoledronate, pamidronate, risedronate, and ibandronate), 136 positive signals were identified, predominantly unlisted in drug labels. This study identifies high-risk and novel ocular AEs related to BPs. These findings warrant further validation in future studies."

Adverse events • Journal • Age-related Macular Degeneration • Cataract • Glaucoma • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders

The preclinical discovery and development of romosozumab for the treatment of people with severe osteoporosis who are at high risk of fracture. (PubMed, Expert Opin Drug Discov) - "Furthermore, sequential treatment, switching romosozumab over to denosumab, reduced the risk of vertebral fractures compared to switching the placebo to denosumab. An imbalance in cardiovascular events was found when using romosozumab in comparison to alendronate but not versus placebo. Romosozumab was eventually approved by EMA and FDA in 2019 for the treatment of patients with very high risk of fractures while considering their cardiovascular risk and is available and reimbursed in many countries."

Journal • Preclinical • Cardiovascular • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • SOST

Clinical Audit on Prevention of Glucocorticoid Induced Osteoporosis in Respiratory Patients (APSR 2025) - "Alendronate (bisphosphonate) was given to 84.6%...Bone protective therapy was prescribed in the majority of the cohort. Major deficiencient areas were osteoporosis risk assessment, lifestyle advise, and patient education about osteoporosis risk and bone protective therapy."

Clinical • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis (clinicaltrials.gov) - P=N/A | N=40 | Recruiting | Sponsor: Khyber Medical University Peshawar

New trial • Osteoporosis • Rheumatology